Similar But Different: Regulatory and Operational Considerations for Biosimilar Clinical Development in IBD  

By Maxim Kosov

MD, PhD, PSI Senior Medical Advisor

The rise of IBD biosimilars and what comes next

Biosimilars present untapped potential for expanding patient access and improving treatment options in Inflammatory Bowel Disease (IBD) and other therapeutic areas, but these trials also bring unique challenges and regulatory considerations.

In this white paper, you’ll learn how biosimilars have transformed the treatment landscape for IBD in the past decade, their current therapeutic uses in Crohn’s disease and ulcerative colitis, and global regulatory considerations for running biosimilar clinical trials in IBD.

Download our new white paper to learn about:

  • IBD epidemiology and current biosimilar treatment methods
  • Regulatory considerations and other challenges for biosimilar trials
  • Future opportunities for biosimilar therapeutics

Share

Agree
I understand that if I would like to receive email communications from PSI regarding PSI products, services, solutions, or events, I need to opt-in with the box. I understand that PSI will process data about me as described in the Privacy Policy and that I can opt out at any time by visiting the Manage your Subscription page.
Agree
I understand that if I would like to receive email communications from PSI regarding PSI products, services, solutions, or events, I need to opt-in with the box. I understand that PSI will process data about me as described in the Privacy Policy and that I can opt out at any time by visiting the Manage your Subscription page.